Study shows AstraZeneca's Covid-19 mAb Evusheld may not work against dominant Omicron...

[cafead]

via AstraZeneca’s prophylactic treatment for Covid-19, known as Evusheld, has survived where other mAbs failed, showing efficacy for the immunocompromised and others who cannot be vaccinated across multiple variants, including Delta and several Omicron subvariants.

article source